ON
← Back to feed
Rhinosinusitis with nasal polyposis, Italian study confirms the effectiveness of mepolizumab
Italy🩺 Health

Rhinosinusitis with nasal polyposis, Italian study confirms the effectiveness of mepolizumab

A Phase 4 real-world study named Meporeal has been published in The Lancet Respiratory Medicine, evaluating the efficacy and safety of mepolizumab for severe, uncontrolled chronic rhinosinusitis with nasal polyposis (CRSwNP). Conducted across 25 Italian specialist centers involving 621 patients, the research represents one of the largest multicenter real-world experiences regarding this biologic therapy. After 12 months of treatment, participants showed significant clinical improvements, including a halving of the median endoscopic severity score from 6 to 3 and a reduction in quality-of-life impact scores from 59 to 21 points. Approximately 42 percent of patients achieved disease control, while around 20 percent met criteria for clinical remission during treatment. The study population was complex, with over half of the patients suffering from concurrent asthma and many having previously undergone surgical interventions for nasal polyps.

2 reports

Il Giornale logoIl GiornaleParty-alignedCenter
Rhinosinusitis with nasal polyposis, Italian study confirms the effectiveness of mepolizumab

A new Italian phase 4 real-world study named Meporeal has confirmed the efficacy and safety of mepolizumab for treating severe, uncontrolled chronic rhinosinusitis with nasal polyposis (CRSwNP). Published in The Lancet Respiratory Medicine, the research involved 621 patients across 25 specialized centers in Italy. After 12 months of treatment, participants showed significant clinical improvements, including a halving of the median endoscopic severity score from 6 to 3 and a reduction in quality-of-life impact scores from 59 to 21 points. Approximately 42 percent of patients achieved disease control, while around 20 percent met criteria for clinical remission during treatment. The study highlights the drug’s benefits in complex patient populations, where over half had concurrent asthma and many had previously undergone surgery.

Bias read (Center): The article presents neutral medical data and quotes academic experts regarding a specific pharmaceutical trial without using loaded language or taking a political stance.

Adnkronos logoAdnkronosIndependentCenter
Rhinosinusitis with nasal polyposis, Italian study confirms the effectiveness of mepolizumab

A Phase 4 real-world study named Meporeal has been published in The Lancet Respiratory Medicine, evaluating the efficacy and safety of mepolizumab for severe, uncontrolled chronic rhinosinusitis with nasal polyposis (CRSwNP). Conducted across 25 Italian specialist centers involving 621 patients, the research represents one of the largest multicenter real-world experiences regarding this biologic therapy. After 12 months of treatment, participants showed significant clinical improvements, including a halving of the median endoscopic severity score from 6 to 3 and a reduction in quality-of-life impact scores from 59 to 21 points. Approximately 42 percent of patients achieved disease control, while around 20 percent met criteria for clinical remission during treatment. The study population was complex, with over half of the patients suffering from concurrent asthma and many having previously undergone surgical interventions for nasal polyps.

Bias read (Center): The article presents neutral medical data and quotes researchers without using loaded language or taking a stance on controversial issues.

How each side covered it

The same event, grouped by the political lean of the outlets covering it.

How each side covered it

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Covered around the world

The same event as reported in other countries.

Covered around the world

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Claims check

Key factual claims, and how many sources assert vs dispute each.

Claims check

Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.

Become a Supporter

Keep the news honest.

ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €4/month.

Become a Supporter

Related stories